Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency

por Maliepaard, Marc, Faber, Yoran S., van Bussel, Mark T. J.
Publicado 2023

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

por van Bussel, Mark T. J., Beijnen, Jos H., Brandsma, Dieta
Publicado 2019

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer

por Tabernero, Josep, Van Cutsem, Eric, Garralda, Elena, Tai, David, De Braud, Filippo, Geva, Ravit, van Bussel, Mark T J, Fiorella Dotti, Katia, Elez, Elena, de Miguel, María J, Litwiler, Kevin, Murphy, Danielle, Edwards, Michelle, Morris, Van Karlyle
Publicado 2023

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

por van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.
Publicado 2020